• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大脊柱关节炎研究联合会脊柱关节炎注册中心。

The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis.

机构信息

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Rheumatol. 2011 Jul;38(7):1343-8. doi: 10.3899/jrheum.101102. Epub 2011 Apr 15.

DOI:10.3899/jrheum.101102
PMID:21498484
Abstract

The Spondyloarthritis Research Consortium of Cananda (SPARCC) is a transdiscliplinary research network of investigators interested in spondyloarthritis. The group has been supported by a new research initiative by The Arthritis Society. SPARCC aims to address the genetic basis of susceptibility of the disease and develop and validate clinical and imaging outcomes to assess disease activity and structural damage over time, the response to therapy, and the clinical burden of illness in terms of quality of life and disability. The first step was to develop a database that would allow ascertainment of phenotype for genetic studies, as well as accurate and detailed longitudinal information for disease expression and outcome studies. This article describes the SPARCC database and outlines difficulties and possible solutions for maintaining such a database.

摘要

加拿大脊柱关节炎研究联合会(SPARCC)是一个跨学科的研究网络,由对脊柱关节炎感兴趣的研究人员组成。该组织得到了关节炎协会新的研究计划的支持。SPARCC 的目标是确定疾病易感性的遗传基础,并开发和验证临床和影像学结果,以评估疾病活动和结构损伤随时间的变化、治疗反应以及疾病对生活质量和残疾的临床负担。第一步是建立一个数据库,以便对遗传研究进行表型确定,并对疾病表达和结果研究进行准确和详细的纵向信息。本文介绍了 SPARCC 数据库,并概述了维护此类数据库的困难和可能的解决方案。

相似文献

1
The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis.加拿大脊柱关节炎研究联合会脊柱关节炎注册中心。
J Rheumatol. 2011 Jul;38(7):1343-8. doi: 10.3899/jrheum.101102. Epub 2011 Apr 15.
2
The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.
J Rheumatol. 2008 Apr;35(4):658-61. Epub 2008 Feb 15.
3
Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis.全身成像与传统磁共振成像用于对脊柱关节炎患者骶髂关节急性炎症性病变进行评分的验证
Arthritis Rheum. 2009 Jul 15;61(7):893-9. doi: 10.1002/art.24542.
4
Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI.评估轴向型脊柱关节炎患者的脊柱活动性炎症改变:全身 MRI 与常规 MRI 的对比验证。
Ann Rheum Dis. 2010 Apr;69(4):648-53. doi: 10.1136/ard.2009.108274. Epub 2009 May 4.
5
Spondyloarthritis: state of the art and future perspectives.脊柱关节炎:现状与未来展望。
Ann Rheum Dis. 2010 Jun;69(6):949-54. doi: 10.1136/ard.2009.119529. Epub 2010 May 5.
6
Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.加拿大风湿病协会关于使用抗肿瘤坏死因子-α定向疗法治疗脊柱关节炎的共识
J Rheumatol. 2003 Jun;30(6):1356-63.
7
The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada.银屑病关节炎患者的临床评估:加拿大脊柱关节炎研究联盟可靠性研究的结果
J Rheumatol. 2004 Jun;31(6):1126-31.
8
HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis.HLA-B27 阳性患者与 HLA-B27 阴性患者在临床表现和影像学上存在差异:来自近期发病的中轴型脊柱关节炎患者 DESIR 队列的研究结果。
Ann Rheum Dis. 2011 Nov;70(11):1930-6. doi: 10.1136/ard.2011.152975. Epub 2011 Jul 28.
9
Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis.ASDAS 评估强直性脊柱炎患者疾病活动度状况的鉴别能力。
Int J Rheum Dis. 2010 Aug;13(3):240-5. doi: 10.1111/j.1756-185X.2010.01537.x.
10
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.制定可溶性生物标志物的验证标准草案,该生物标志物在类风湿性关节炎和脊柱关节炎临床试验中被视为反映结构损伤终点的有效生物标志物。
J Rheumatol. 2007 Mar;34(3):634-40.

引用本文的文献

1
Spectrum of Spondyloarthritis Among Chinese Populations.中国人群中脊柱关节炎的分布情况。
Curr Rheumatol Rep. 2022 Aug;24(8):247-258. doi: 10.1007/s11926-022-01079-1. Epub 2022 Jul 13.
2
Comparison of Clinical Features in HLA-B27 Positive and Negative Patients With Axial Spondyloarthritis: Results From a Cohort of 4,131 Patients.HLA-B27阳性和阴性的轴性脊柱关节炎患者临床特征比较:来自4131例患者队列的结果
Front Med (Lausanne). 2020 Dec 23;7:609562. doi: 10.3389/fmed.2020.609562. eCollection 2020.
3
Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.
中轴型脊柱关节炎合并症的患病率和影响:系统评价和荟萃分析。
Rheumatology (Oxford). 2020 Oct 1;59(Suppl4):iv47-iv57. doi: 10.1093/rheumatology/keaa246.
4
Does evaluation of the ligamentous compartment enhance diagnostic utility of sacroiliac joint MRI in axial spondyloarthritis?评估韧带间隙是否能提高骶髂关节MRI在轴性脊柱关节炎中的诊断效用?
Arthritis Res Ther. 2015 Sep 13;17(1):246. doi: 10.1186/s13075-015-0729-8.
5
Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis.肿瘤坏死因子抑制剂疗法而非标准疗法与轴性脊柱关节炎患者骶髂关节侵蚀的消退相关。
Arthritis Res Ther. 2014 Apr 22;16(2):R100. doi: 10.1186/ar4548.
6
A registry of ankylosing spondylitis registries and prospects for global interfacing.强直性脊柱炎注册中心及全球对接的前景。
Curr Opin Rheumatol. 2013 Jul;25(4):468-76. doi: 10.1097/BOR.0b013e3283620e1d.